"Committee members, you're about to see: resumés without logos. And I implore you to rank the resumé and not the logo. Because if you do that, I think Indiana is going to be a lot higher than ...

Sciwind plans to develop the lead GIP receptor agonist as part of combination with its GLP-1 peptide candidate, XW003 which is currently being evaluated in Phase 2 studies, for the treatment of ...